Arcturus Therapeutics

Arcturus Therapeutics

  • Founded: 2013
  • Location: San Diego, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin3
  • Therapy area: COVID-19
  • Drug types: INF, GEN, VAC, LNG
  • Lead product: LUNAR-COV19 (partner: CSL)
  • Product link:
  • Funding: $173M stock Jul 2020; $70M stock Apr 2020; $9.8M stock Sep 2019; $2.3M stock Aug 2019

job board

Short description:

Lipid nanoparticle (LNP) mRNA drug delivery systems

Drug notes:

ARCT-810 Clin2 ornithine transcarbamylase deficiency; LUNAR -GSDIII Clin1/Clin2 glycogen storage disease type III (partner: Ultragenyx); LUNAR-CF Clin1 cystic fibrosis; LUNAR-FLU Clin0 influenza

Long description:

Arcturus Therapeutics is using RNA technology to develop rare and infectious diseases therapeutics. Different forms of RNA can be used as a protein replacement therapy to treat diseases that lack a protein, gene editing, gene silencing and as vaccines. Arcturus is capitalizing on these strategies to create RNA medicines. The main challenges are identifying the most potent and specific RNA sequence and delivery of the therapeutic RNA to the desired cells. To achieve this, Arcturus is employing their Lipid-Mediated Delivery Enables Multiple RNA Medicines (LUNAR®) technology, a proprietary multi-component drug delivery system that is versatile, scalable and reproducible. Arcturus has leveraged their LUNAR platform to create a vaccine for COVID-19 which is in Phase 3 clinical trials.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy